Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
AbbVie’s Rova-T Sees Another Failure
Acquisitions, Advanced small-cell lung cancer, Antibody Drug Conjugates (ADC), Blockbusters, Cancer Cells, Clinical Trials, Data Monitoring Committee (DMC), Delta-like protein 3 (DLL3), Glioblastoma Multiforme (GBM), R&D, Small cell lung cancer, Stocks, Tumor CellsAbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain
Antigens, Brain Cancer, China Food and Drug Administration, Clinical Trials, Clinical Trials, Gene Therapy, Glioblastoma Multiforme (GBM), Immunotherapies, National Institute of Health, Proteasome Inhibitors, R&D, Rare Diseases, Small MoleculesCiting the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.
Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
The U.S. Food and Drug Administration granted orphan drug designation to PharmAbcine Inc.’s leading clinical compound TTAC-0001 for the treatment of glioblastoma multiforme.
Mid-stage data shows that Pfizer’s lorlatinib could provide benefits to lung cancer patients who exhibit related brain tumors.
The number of U.S. adults and children with epilepsy is increasing, with at least 3.4 million people living with the disorder, according to data released in CDC’s Morbidity and Mortality Weekly Report. This is the first time epilepsy estimates have been available for every state.
2017 Annual Report – Top 200 Medicines: Humira Remains Atop The Throne
Analysts, August 2017, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Blockbusters, Blood Cancers, Breast Cancer, Cervical Cancer, Colorectal Cancer, Forecasts, Forecasts, Gastroenterology, Hepatitis C, Immunology, Inflammatory Diseases, Japan, Kidney Cancer, Mantle Cell Lymphoma (MCL), Multiple Myeloma, Ovarian Cancer, Pneumococcal Disease, Pneumonia, Relapsed Glioblastoma, Rheumatoid Arthritis, Rheumatology, Special Reports, Therapeutics, Top 200 Medicines, Tumor Necrosis Factor (TNF) Inhibitors, Ulcerative Colitis, Vaccines, VasculitisAbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
AstraZeneca’s pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial.